Left for Dead Valeant Pharma (VRX) Is Up 30% In a Week

Short seller target Valeant Pharma (NYSE: VRX) is continuing to rally sharply off oversold conditions following a few modest positives over the past week or so:

• Citi launched coverage on the debt with an Overweight rating
• Valeant products are selling ex-Philidor
• Valeant to offer cash, stock to keep staff after turmoil
• Positive analyst comments: Morgan Stanley, Mizuho

While nothing is a huge positive catalyst in and of itself, taken together the positives are enough to persuade shorts to lock in gains and move on.

Shares are up 6.5% today and 29% since the start of last week.

You May Also Be Interested In

• Inflation relief has likely been delayed not destroyed - GS
• Instacart (CART), DoorDash (DASH), Uber (UBER) on Watch After Amazon (AMZN) Launches Grocery Delivery Subscription
• Pinterest (PINS) Mentioned Positively at Edgewater